Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Q3 2025 Earnings Presentation
36 slides from Bico Group Ab Class B's earnings presentation, Nov 4, 2025
Slide 1: Interim Report Q3 2025 Earnings Call
INTERIM REPORT Q3 2025 EARNINGS CALL 2025-11-04 – TUESDAY NOVEMBER 4 , 2025
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 3: Earnings Call Agenda Q3 2025
Earnings Call Agenda Q3 2025 Summary of the Quarter Group Financial Performance Life Science Solutions Lab Automation Maria Forss Jacob Thordenberg Continuous Product Innovation President & CEO CFO Concluding Remarks Q&A 3
Slide 4: BICO's Portfolio
BICO’s Portfolio Serving the World´s leading Pharma and Biotech companies 3D bioprinting products for tissue Lab automation software and robotics Dispensing automation for applications engineering and regenerative integrations provider. GBG SW gives an requiring precise deposition of biological medi
Slide 5: The Global Challenge
The Global Challenge Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry Drug discovery Product development Process development Production > USD 2bn ~ 10% > 10 years Probability of approval Development costs Discovery to approv
Slide 6: Providing the data backbone unifying AI-powered services with lab automation
Providing the data backbone unifying AI-powered services with lab automation Powering AI drug discovery workflows, using the Green Button Go platform. Enabling our customers to apply AI and ML to optimize experimentation and decision making in R&D to SPEED ACCURACY EFFICIENCY Reduce the timelines Be
Slide 7: Vision
Vision BICO enables and automates the life science Mission lab of the future Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 7
Slide 8: Lab Automation Video
LAB AUTOMATION VIDEO 8
Slide 9: BICO Leads the way in Solving the Challenges in Life Science
BICO Leads the way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency • Reducing the time to find optimal candidates for treatment Speed therapies • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models Accuracy
Slide 10: Summary of the Quarter
Summary of the Quarter 1010
Slide 11: Key Take Aways Q3 2025
Key Take Aways I Q3 2025 • Life Science Solutions showed 4 percent organic sales growth YoY • Lab Automation delivered 35 percent organic sales growth YoY • Biosero received orders from a global pharma company worth USD 15.2m, as part of a master framework agreement • Impairments of SEK 1,036m in Di
Slide 12: Summary Q3 2025
Summary I Q3 2025 CASH FLOW FROM NET SALES ADJUSTED EBITDA OPERATING ACTIVITIES SEK 387m SEK 17m SEK -32m ORGANIC SALES ADJUSTED NWC/LTM SALES GROWTH EBITDA MARGIN 12% 5% 13% All numbers in this report refer to continuing operations if not otherwise stated. Ginolis, Nanoscribe, MatTek and Visikol ha
Slide 13: Transformative Actions to Scale up Biosero
Transformative Actions to Scale up Biosero Continued execution of comprehensive action plan New Managing Director in Biosero Significantly enhancing processes and operational capabilities Substantial investments in operational resources, for the benefit of our customers, to accelerate closing of del
Slide 14: Strengthened Cash Position Through Divestment of MatTek and Visikol
Strengthened Cash Position Through Divestment of MatTek and Visikol • Divestments of MatTek and Visikol generated net proceeds of SEK 740m, significantly strengthening the cash position • This divestment follows our updated strategy with a focus on lab automation and selected workflows • Sartorius a
Slide 15: Impairments in Discover ECHO and Biosero
Impairments in Discover ECHO and Biosero • Impairments of SEK 1,036m in Discover ECHO and Biosero which are non-cash flow affecting one-off items affecting EBIT • Strong underlying demand for Biosero’s integrated lab automation solutions centered around the company’s market leading software suite, G
Slide 16: Group Financial Performance
Group Financial Performance 1616
Slide 17: Sales Development (SEKm)
Sales Development (SEKm) SEKm 5%* 600 • Sales amounted to SEK 387m 515 and generated a sales growth of 500 5 percent and an organic sales growth of 12 percent 369 387 400 • The 7-percentage point difference between sales growth and organic 335 324 sales growth can mainly be explained by a weaker US
Slide 18: Adjusted EBITDA (SEKm) and Margin (%)
Adjusted EBITDA (SEKm) and Margin (%) SEKm % 140 127 30 120 25% 25 • Adjusted EBITDA SEK 17m corresponding to a margin of 100 20 5 percent 80 15 • The improved margin is a result of continued cost control activities, 60 10 mainly from centralization of functions as well as initiatives for 40 5% 5 op
Slide 19: Cash Flow and Financial Position
Cash Flow and Financial Position • Cash flow from operating activities, SEK -32m • This includes an effect from changes in working capital of SEK -30m • Total cash flow during Q3, SEK 570m • MatTek and Visikol divested as of July 1, 2025, and net proceeds amounted to SEK 740m • Bond-buy back on Augu
Slide 20: Development in Net Working Capital Between Q3 2024 and Q3 2025
Development in Net Working Capital Between Q3 2024 and Q3 2025* SEKm 1,400 40.0% 1,050 30.0% 21.6% 700 20.2% 20.0% WC Liabilities Other Receivables 12.4% 12.5% 350 374 10.9% 10.0% Accounts Receivables 349 Inventories 203 195 169 Total NWC 0 0.0% NWC / LTM Sales -350 -10.0% -700 -20.0% Q3 24 Q4 24 Q1
Slide 21: Life Science Solutions
Life Science Solutions 21 21
Slide 22: Life Science Solutions Q3 2025
Life Science Solutions I Q3 2025 Rolling 12 months Net sales and adjusted EBITDA margin 263 4 NET SALES ORGANIC SALES SEK m GROWTH % 19 7 ADJUSTED EBITDA ADJUSTED EBITDA SEK m MARGIN % 22
Slide 23: Lab Automation
Lab Automation 2323
Slide 24: Lab Automation Q3 2025
Lab Automation I Q3 2025 Rolling 12 months Net sales and adjusted EBITDA margin 124 35 NET SALES ORGANIC SALES SEK m GROWTH % 10 8 ADJUSTED EBITDA ADJUSTED EBITDA SEK m MARGIN % 24
Slide 25: Continuous Product Innovation
Continuous Product Innovation 25 25
Slide 26: Laboratory Automation Products and Solutions in both Business Areas
Laboratory Automation Products and Solutions in both Business Areas MANUAL SEMI-AUTOMATED AUTOMATED FULLY AUTOMATED INTEGRATED Revolve BIO X6 C.WASH Plus I.DOT LT TurnStation CellenOne S100 C.STATION Lab Experience, Green Button Go Suite Lab Experience Lab Experience Scheduler Scheduler & Orchestrat
Slide 27: I.DOT LT: Precision Dispensing Made Accessible and Reliable
I.DOT LT: Precision Dispensing Made Accessible and Reliable • The I.DOT LT a new addition in the I.DOT series • A compact solution optimized for automated low-volume liquid dispensing Green Button Go® Ready 27
Slide 28: Driving Growth Through Synergies
Driving Growth Through Synergies: TurnStation by QINSTRUMENTS Integrated by Biosero’s Green Button Go® • Commercial synergies within the Group • TurnStation optimizes the workflow for microplate handling, purpose-built for seamless lab automation • TurnStation included in Biosero’s Green Button Go®
Slide 29: Octet and Green Button Go
Octet® and Green Button Go® Integrated lab automation solution bringing faster results to the market Enabled by Green Button Go® 29
Slide 30: R&D Pipeline & Roadmap
Instrument Software R&D Pipeline & Roadmap Consumable Product Portfolio 2025 2026 2027 2028 Lab Automation Software Standardized Lab Automation Go Simple Lab Automation Components Bioprinting Precision Dispenser Liquid Handling Single-cell Dispenser Live-cell Imaging Microscopes 30
Slide 31: Concluding Remarks
Concluding Remarks 31
Slide 32: BICO 2.0 a Year of Progress
BICO 2.0 a Year of Progress One year ago, we launched BICO 2.0, our updated strategy to enable and automate the life science lab of the future Streamlined portfolio, strengthened commercial engine, invested in people and culture, and delivered operational excellence Strengthened cash position, leane
Slide 33: Q&A
Q&A 33
Slide 34: 2025-11-04
2025-11-04
Slide 35: Financial Calendar Contact
Financial Calendar Contact FEBRUARY 18, 2026 Year-end report 2025 MARIA FORSS, CEO AND PRESIDENT JACOB THORDENBERG, CFO BICO GROUP AB BICO GROUP AB MARCH 18, 2026 Phone: EA Isabella Lundin, +46 735 15 99 64 Phone: +46 73 534 88 84 Annual Report 2025 E-mail: jt@bico.com E-mail: mf@bico.com APRIL 29,
Slide 36: 2025-11-04
2025-11-04